Patents by Inventor Mareike Grees

Mareike Grees has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11998539
    Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: June 4, 2024
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Norbert Schmees, Lars Wortmann, Dennis Kirchhoff, Thi Thanh Uyen Nguyen, Nicolas Werbeck, Ulf Bömer, Kirstin Petersen, Christina Kober, Christian Lechner, Dirk Kosemund, Rienk Offringa, Mareike Grees, Benjamin Bader
  • Patent number: 11964953
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: April 23, 2024
    Assignees: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert Schmees, Ulrike Roehn, Dennis Kirchhoff, Kirstin Petersen, Mareike Grees, Nicolas Werbeck, Benjamin Bader, Rienk Offringa, Corinna Link
  • Publication number: 20210030856
    Abstract: The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4+T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHCII binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4+T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.
    Type: Application
    Filed: March 26, 2019
    Publication date: February 4, 2021
    Applicants: Deutsches Krebsforschungszentrum Stiftung des Ă–ffentlichen Rechts, Yeda Research and Development Co., Ltd.
    Inventors: Rachel Lea Eisenbach, Esther Tzehoval, Gal Cafri, Adi Sharbi Yunger, Mareike Grees